Mucoright 100mg Granules For Suspension Philippines - English - FDA (Food And Drug Administration)

mucoright 100mg granules for suspension

medethix, inc,; distributor: medethix, inc, - acetylcysteine - granules for suspension - 100mg

Mucoright 200 mg Granules For Suspension Philippines - English - FDA (Food And Drug Administration)

mucoright 200 mg granules for suspension

medethix, inc.; distributor: medethix, inc. - acetylcysteine - granules for suspension - 200 mg

Mucoright 100 mg/5 mL Syrup Philippines - English - FDA (Food And Drug Administration)

mucoright 100 mg/5 ml syrup

medexthix, inc.; distributor: medexthix, inc. - acetylcysteine - syrup - 100 mg/5 ml

Mucoright 100 mg/mL Solution For Inhalation Philippines - English - FDA (Food And Drug Administration)

mucoright 100 mg/ml solution for inhalation

medethix, inc.; distributor: medethix, inc. - acetylcysteine - solution for inhalation - 100 mg/ml

Mucorex 4mg Tablet Philippines - English - FDA (Food And Drug Administration)

mucorex 4mg tablet

new myrex labs inc - bromhexine hydrochloride - tablet - 4mg

Mucoright 600 mg Effervescent Tablet (ORange Flavor) Philippines - English - FDA (Food And Drug Administration)

mucoright 600 mg effervescent tablet (orange flavor)

alvita pharma pvt. ltd.; importer: medethix, inc.; distributor: medethix, inc. - acetylcysteine - effervescent tablet (orange flavor) - 600 mg

ANIMAL ALLERGENS, AP CATTLE HAIR AND DANDER- cattle hair and dander injection, solution ANIMAL ALLERGENS, AP DOG HAIR AND DANDE United States - English - NLM (National Library of Medicine)

animal allergens, ap cattle hair and dander- cattle hair and dander injection, solution animal allergens, ap dog hair and dande

jubilant hollisterstier llc - bos taurus hair (unii: toq97z8644) (bos taurus hair - unii:toq97z8644), bos taurus dander (unii: c8vys726o8) (bos taurus dander - unii:c8vys726o8) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

FOOD - PLANT SOURCE, YEAST, BAKER SACCHAROMYCES CEREVISIAE- yeast, baker saccharomyces cerevisiae injection, solution FOOD - PL United States - English - NLM (National Library of Medicine)

food - plant source, yeast, baker saccharomyces cerevisiae- yeast, baker saccharomyces cerevisiae injection, solution food - pl

jubilant hollisterstier llc - yeast (unii: 3ny3sm6b8u) (yeast - unii:3ny3sm6b8u) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

ITRACAP itraconazole 100 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

itracap itraconazole 100 mg capsule blister pack

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

ITRANOX itraconazole 100 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

itranox itraconazole 100 mg capsule blister pack

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itranox is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.